When Danish drugmaker Novo Nordisk reports its quarterly financial results on Wednesday, investors will be looking for reassurance the GLP-1 market is still on track for the enormous growth Wall ...

Novo Nordisk (NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP-1 drug, CagriSema. The drug, a mix of cagrilintide and ...

(Bloomberg) -- Novo Nordisk A/S shares plunged the most since December after another disappointment for the drugmaker’s next-generation shot CagriSema. The medicine helped patients with diabetes ...

Novo Nordisk (NVO) plans to run studies on how its GLP-1 class of weight loss/diabetes drug can help people deal with addiction, Martin Holst Lange, the Danish pharma’s head of development ...

Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are no longer in short supply. This caused the United States Food and Drug ...

Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist. The Danish pharma ...

Novo Nordisk shares have dropped significantly ... Amycretin's promising early-stage results and the optimistic market forecasts for GLP-1 drugs and obesity care suggest that there's lots of ...

from KBP Biosciences for up to $1.3 billion. However, in June 2024 Novo Nordisk said it was recognising a loss of around 5.7 billion Danish crowns ($800 million) in relation to the drug after ...

Yet a new study suggests surprising new uses for Novo's Ozempic. And why? Monday's decline probably owes to rival GLP-1 company Hims & Hers Health running a high-publicity ad during the Super ...

Novo Nordisk is cutting the cost of its blockbuster ... This includes 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg dose strengths. The list price of the drug before insurance and certain rebates ...